Implant Sciences Corporation
(OTCQB: IMSC) is a leader in the development and manufacture of advanced
detection technologies designed to counter and eliminate the ever-evolving
threats presented by explosives and drugs. The company’s explosives trace detection
(ETD) and drugs trace detection solutions target a wide variety of vital
security applications – including aviation, transportation, customs, air cargo,
critical infrastructure protection, port and border protection, public safety
and emergency first responders. Since its founding in 1984, Implant Sciences
has recorded a rich history of innovation in several markets, such as medical
products and semiconductor manufacturing, however, in 2008, the company
restructured to become a pure play in the global Security Safety and Defense
(SS&D) markets.
Over the past decade, Implant
Sciences’ team of dedicated trace detection experts has leveraged an expansive
intellectual property portfolio in order to develop proprietary technologies
addressing unmet needs in the global SS&D industry. To date, the company’s
patented technology, used in flagship products such as the QS-H150 handheld
explosives trace detector and the QS-B220 desktop explosive and drugs trace
detector, has been sold in more than 50 countries around the globe.
Additionally, Implant Sciences’ ETDs have received approvals and certifications
from several international regulatory agencies – including the Transportation
Security Administration in the United States; the European Civil Aviation
Conference; the Ministry of Public Safety and the Civil Aviation Administration
of China; and the Federal Security Service of the Russian Federation, among
others.
In the months to come, Implant
Sciences will look to draw on its considerable experience in advanced ion
technologies in order to further refine and expand upon its impressive catalog
of trace detection technologies. This progress should strategically position
the company to continue capitalizing on the projected growth of the global ETD
market for the foreseeable future.
According to a report
(http://dtn.fm/P5a4H) from leading international market and technology research
firm Homeland Security Research, the global ETD market – including systems,
sales, services, consumables and upgrades – will present multibillion-dollar
business opportunities through 2020, expanding at a compound annual growth rate
(CAGR) of 12.7 percent. Key to this growth will be strong demand from the
Asia-Pacific region, driven by factors such as a massive investment in new
airports and public security by the Chinese government, counterterror
investments from the Indian government and strict legislations from the U.S.
and European Union regarding cargo screenings on international passenger
flights from the region. In total, the Asia-Pacific ETD market is on pace to
achieve a CAGR of roughly 15 percent over the seven-year period ending in 2020.
In its latest financial report,
released earlier this month, Implant Sciences gave prospective investors a
preview of its potential in these favorable market conditions. During the
fiscal quarter ended December 31, 2015, the company achieved a year-over-year
increase in revenues in excess of 380 percent, recording $10.3 million for the
three-month period. The bulk of this growth was attributed to the delivery of a
substantial order with the U.S. Transportation Security Administration,
increased shipments to European airports and increased shipments to Asia,
Africa and South America. The result was an 818 percent increase in the number
of QS-B220 desktop units sold, as compared to the same period in 2014.
By achieving strong revenue
growth, Implant Sciences is effectively demonstrating its capabilities from not
only a manufacturing and supply chain perspective, but also from a working
capital management perspective. In a recent news release, Dr. William McGann,
chief executive officer of Implant Sciences, echoed this optimism when
discussing the company’s recent progress toward becoming self-sufficient,
reiterating the tremendous potential offered to prospective shareholders by
this pure play in the global SS&D industry in the coming years.
“Thus far this year, we have
successfully self-funded the significant working capital required to deliver
the record revenues being reported today,” he stated. “We’re continuing to
invest and expect to increase our investment in technology, with the intent
[to] introduce new product that will increase the size of the security market
we can penetrate.”
For more information, visit www.implantsciences.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment